Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report), Atrys Health SA (DE:A2T – Research Report) and GlaxoSmithKline (GB:GSK – Research Report).
Atrys Health SA (DE:A2T)
In a report issued on July 14, Pablo de Renteria from Kepler Capital maintained a Buy rating on Atrys Health SA, with a price target of EUR6.40. The company’s shares closed yesterday at EUR5.04.
According to TipRanks.com, Renteria is ranked #8054 out of 8514 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atrys Health SA with an EUR6.40 average price target.
GlaxoSmithKline (GB:GSK)
In a report released yesterday, Graham Parry from Bank of America Securities reiterated a Sell rating on GlaxoSmithKline, with a price target of p1390.00. The company’s shares closed last Tuesday at p1325.40.
According to TipRanks.com, Parry is a 3-star analyst with an average return of
GlaxoSmithKline has an analyst consensus of Hold, with a price target consensus of p1373.71, representing a 4.4% upside. In a report issued on July 14, HSBC also initiated coverage with a Sell rating on the stock with a p1190.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMED:
